Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease

Gianotti, Lorena R. R. and Künig, Gabriella and Faber, Pascal L. and Lehmann, Dietrich and Pascual-Marqui, Roberto D. and Kochi, Kieko and Schreiter-Gasser, Ursula. (2008) Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease. Psychopharmacology, Vol. 198, no. 3. pp. 323-332.

[img] PDF
Restricted to Repository staff only


Official URL: http://edoc.unibas.ch/dok/A5844627

Downloads: Statistics Overview


The objective of the study is to investigate the electrocortical and the global cognitive effects of 3 months rivastigmine medication in a group of mild to moderate Alzheimer's disease patients.; Multichannel EEG and cognitive performances measured with the Mini Mental State Examination in a group of 16 patients with mild to moderate Alzheimer's Disease were collected before and 3 months after the onset of rivastigmine medication.; Spectral analysis of the EEG data showed a significant power decrease in the delta and theta frequency bands during rivastigmine medication, i.e., a shift of the power spectrum towards 'normalization'. Three-dimensional low resolution electromagnetic tomography (LORETA) functional imaging localized rivastigmine effects in a network that includes left fronto-parietal regions, posterior cingulate cortex, bilateral parahippocampal regions, and the hippocampus. Moreover, a correlation analysis between differences in the cognitive performances during the two recordings and LORETA-computed intracortical activity showed, in the alpha1 frequency band, better cognitive performance with increased cortical activity in the left insula.; The results point to a 'normalization' of the EEG power spectrum due to medication, and the intracortical localization of these effects showed an increase of cortical activity in frontal, parietal, and temporal regions that are well-known to be affected in Alzheimer's disease. The topographic convergence of the present results with the memory network proposed by Vincent et al. (J. Neurophysiol. 96:3517-3531, 2006) leads to the speculation that in our group of patients, rivastigmine specifically activates brain regions that are involved in memory functions, notably a key symptom in this degenerative disease.
UniBasel Contributors:Gianotti, Lorena R. R.
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
edoc DOI:
Last Modified:31 Dec 2015 10:50
Deposited On:14 Sep 2012 07:12

Repository Staff Only: item control page